Summary of available biomarker results
| PD-L1 | DNA-Seq (FoundationOne CDx) | NanoString (TIS) | Digital IHC (CD8) | Multiplex IHC | RNA-Seq | Flow Cytometry | Cytokine Profiling (n=21) | Targeted DNA-Seq (ctDNA) | |
| Sample number, n | 477 | 443 (TMB, 414) | 433 | 419 | 339 | 395 | Baseline, 409; week 4, 405 | Baseline, 511; week 4, 479 | Baseline, 481; week 8, 440 |
| % of intention-to-treat population (N=532) | 90 | 83 (TMB, 78) | 81 | 79 | 64 | 74 | Baseline, 77; week 4, 76 | Baseline, 96; week 4, 90 | Baseline, 90; week 8, 83 |
All numbers refer to baseline samples, unless otherwise indicated.
CD, cluster of differentiation; ctDNA, circulating tumor DNA; DNA-seq, DNA sequencing; IHC, immunohistochemistry; PD-L1, programmed death ligand 1; RNA-seq, RNA sequencing; TIS, T-cell-inflamed signature; TMB, tumor mutational burden.